A leader in the discovery of oral direct-acting antiviral therapies.
Derived from Atea’s nucleos(t)ide platform, bemnifosbuvir (AT-527) is an oral direct acting antiviral being evaluated in the global Phase 3 SUNRISE-3 registrational trial for the treatment of COVID-19. Bemnifosbuvir targets the SARS-CoV-2 RNA polymerase (nsp12), a highly conserved gene that is unlikely to change as the virus mutates and new variants continue to emerge. This gene is responsible for both replication and transcription of SARS-CoV-2. Bemnifosbuvir has a unique mechanism of action, with dual targets consisting of chain termination (RdRp) and nucleotityltransferase (NiRAN) inhibition, which has the potential to create a high barrier to resistance.